Literature DB >> 8505642

Clinical implementation of anti-acetylcholine receptor antibodies.

F E Somnier1.   

Abstract

A multivariate analysis of anti-acetylcholine receptor (AChR) antibodies and clinical parameters other than treatment (modified Osserman groups, age, type of onset, sex, and thymus pathology) was performed for all incident (n = 366) myasthenia gravis (MG) cases in its white population in Denmark during the past 15 years. Sera from 244 healthy individuals and from 295 patients with diseases other than MG were analysed as controls. Formal statistics for the anti-AChR antibodies assay (immunoprecipitation RIA using crude human AChR extract) were calculated. The distribution of antibodies titres greater than 0.1 nMole/l was found to be approximately lognormal. For MG patients the 95% reference interval was 0.2-1549 nMoles/l, and in control sera the range was 0.0-0.4 nMole/l. Using 0.5 nMole/l as the cut-off level and regarding all results less than this value as normal titres, it appeared that the assay was highly specific (> 99.99%) for MG. In a population of MG patients significance should be attributed to values in the range 0.3-0.4 nMole/l. The overall diagnostic sensitivity was found to be 88%. The sensitivity appeared to be proportionate to clinical severity of MG. The percentage with a normal titre was higher (16%) for early onset of MG, compared with 7% for late onset. No significant difference in relation to the frequency of "negative titre" was found in relation to sex. Anti-AChR antibodies titre was found to correlate with clinical severity, female or male gender, and pathology of thymus. The groups of MG patients were not matched for the various clinical parameters but multiple regression analysis controlling for these variables revealed independent effects of clinical severity and sex though not of age. Normal thymus (including involuted gland) and thymoma were correlated with low to intermediate tires, and hyperplastic thymus with high level of antibodies. The clinical implementation of anti-AchR antibodies is reviewed from 1976 and up to the present. The problems with false positive results are thoroughly expounded.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505642      PMCID: PMC1015008          DOI: 10.1136/jnnp.56.5.496

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  41 in total

1.  The pathology of the thymus gland in myasthenia gravis.

Authors:  B Castleman
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

2.  Anti-acetycholine receptor antibodies in penicillamine treated patients without myasthenia gravis.

Authors:  V M Martin; A Vincent; C Clarke
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

3.  Immune disease and HLA associations with myasthenia gravis.

Authors:  P O Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

4.  Clinical and immunological associations in myasthenia gravis. 1: Autoantibodies.

Authors:  H J Sagar; K Gelsthorpe; A Milford-Ward; G A Davies-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

5.  False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis.

Authors:  T W Mittag; J Caroscio
Journal:  N Engl J Med       Date:  1980-04-10       Impact factor: 91.245

6.  Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis.

Authors:  R C Bucknall; J Dixon A St; E N Glick; J Woodland; D W Zutshi
Journal:  Br Med J       Date:  1975-03-15

7.  Anti-acetylcholine receptor antibodies.

Authors:  A Vincent; J Newsom Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

8.  Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody.

Authors:  E Bartoccioni; F Scuderi; C Scoppetta; A Evoli; P Tonali; L Guidi; C Bartoloni; T Terranova
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

9.  [The significance of determining antibodies to acetylcholine receptor in myasthenia gravis (author's transl)].

Authors:  K V Toyka; T Becker; A Fateh-Moghadam; U A Besinger; G Brehm; D Neumeier; K Heininger; K L Birnberger
Journal:  Klin Wochenschr       Date:  1979-09-17

10.  Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis.

Authors:  S Cuénoud; T E Feltkamp; B W Fulpius; H J Oosterhuis
Journal:  Neurology       Date:  1980-02       Impact factor: 9.910

View more
  13 in total

1.  Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?

Authors:  Gabriele Monte; Gregorio Spagni; Valentina Damato; Raffaele Iorio; Mariapaola Marino; Amelia Evoli
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

2.  Cut off selection in anti-acetylcholine receptor antibody determination.

Authors:  J C Martínez-Castrillo; L M Orensanz; A Jiménez-Escrig; E Somoza
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 3.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250

4.  C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

Authors:  Florencia Aguirre; Analisa Manin; Victoria C Fernandez; Mariano E Justo; Juliana Leoni; Mariela L Paz; Andres M Villa
Journal:  Ther Adv Neurol Disord       Date:  2020-08-10       Impact factor: 6.570

5.  Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

Authors:  Crandall E Peeler; Lindsey B De Lott; Lina Nagia; Joao Lemos; Eric R Eggenberger; Wayne T Cornblath
Journal:  JAMA Neurol       Date:  2015-10       Impact factor: 18.302

6.  Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications.

Authors:  Kaori Noridomi; Go Watanabe; Melissa N Hansen; Gye Won Han; Lin Chen
Journal:  Elife       Date:  2017-04-25       Impact factor: 8.140

7.  Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder.

Authors:  Carolin Hoffmann; Jo Stevens; Shenghua Zong; Daan van Kruining; Abhishek Saxena; Cem İsmail Küçükali; Erdem Tüzün; Nazlı Yalçınkaya; Marc De Hert; Emiliano González-Vioque; Celso Arango; Jon Lindstrom; Marc H De Baets; Bart P F Rutten; Jim van Os; Peter Molenaar; Mario Losen; Pilar Martinez-Martinez
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

8.  Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Authors:  Srikanth Muppidi; Kimiaki Utsugisawa; Michael Benatar; Hiroyuki Murai; Richard J Barohn; Isabel Illa; Saiju Jacob; John Vissing; Ted M Burns; John T Kissel; Richard J Nowak; Henning Andersen; Carlos Casasnovas; Jan L de Bleecker; Tuan H Vu; Renato Mantegazza; Fanny L O'Brien; Jing Jing Wang; Kenji P Fujita; James F Howard
Journal:  Muscle Nerve       Date:  2019-03-08       Impact factor: 3.217

9.  A Case Report of Congenital Fiber Type Disproportion with an Increased Level of Anti-ACh Receptor Antibodies.

Authors:  Shigemi Kimura; Shiro Ozasa; Keiko Nomura; Hirofumi Kosuge; Kowasi Yoshioka
Journal:  Case Rep Pediatr       Date:  2013-05-16

Review 10.  Update on ocular myasthenia gravis in Taiwan.

Authors:  Chao-Wen Lin; Ta-Ching Chen; Jieh-Ren Jou; Lin-Chung Woung
Journal:  Taiwan J Ophthalmol       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.